Pregabalin (Pfizer).
Pregabalin is a gamma-aminobutyric acid analog that is under development by Pfizer for the potential treatment of central nervous system disorders, including epilepsy, neuropathic pain, fibromyalgia and generalized anxiety disorder. By April 2003, Pfizer had filed for approval of pregabalin in Europe for neuropathic pain and as an adjunctive therapy for epilepsy, and in October 2003 an NDA was filed for these indications and generalized anxiety disorder. At this time, phase III trials in fibromyalgia were ongoing.
Axovan Ltd., Innovation Center, Gewerbestrasse 16, CH-4123 Allschwil, Switzerland. richard.huckle@axovan.com
Richard
R
Huckle
D018712:Analgesics, Non-Narcotic / Q000737:chemistry / Q000493:pharmacokinetics* / Q000627:therapeutic use; D000818:Animals; D000927:Anticonvulsants / Q000737:chemistry / Q000493:pharmacokinetics* / Q000627:therapeutic use; D001008:Anxiety Disorders / Q000188:drug therapy; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D010146:Pain / Q000188:drug therapy; D000069583:Pregabalin; D012640:Seizures / Q000188:drug therapy; D013329:Structure-Activity Relationship; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics* / Q000627:therapeutic use
D018712:Analgesics, Non-Narcotic; D000927:Anticonvulsants; D000069583:Pregabalin; D005680:gamma-Aminobutyric Acid